The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Glofitamab and obinutuzumab as first-line therapy for patients with high-tumor burden FL
Reid Merryman, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the first results of a Phase II trial (NCT05783596) evaluating the combination of glofitamab and obinutuzumab as first-line therapy for patients with high-tumor-burden follicular lymphoma (FL), highlighting the combination’s encouraging efficacy. Dr Merryman notes that the regimen was well-tolerated, with the majority of cytokine release syndrome (CRS) cases being grade one. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
